RecruitingNCT06468124

Sensitivity of Organoids to Predict Treatment Outcome in Breast Cancer Metastases

Prospective Study to Correlate the Treatment Sensitivity of Patient-derived Organoids With Clinical Outcomes in Breast Cancer Patients With Brain and/or Extra-cranial Metastases

Sponsor

King's College London

Enrollment

20 participants

Start Date

May 27, 2025

Study Type

OBSERVATIONAL

Conditions

Breast Neoplasms

Summary

The aim of the study is to generate patient-derived organoids (PDOs) from brain resection or biopsied extra-cranial metastases. The preliminary data collected will be used to assess the ability of PDOs to predict patients' treatment response and their radio-sensitivity and chemo-sensitivity can be correlated with their survival outcome.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether tiny lab-grown tumor models (called organoids, made from a patient's own cancer cells) can predict how well a breast cancer patient will respond to treatment. The goal is to better match patients to effective therapies. **You may be eligible if...** - You have breast cancer that has spread to the brain and are scheduled for surgery to remove the tumor - You have breast cancer that has spread elsewhere in the body and are undergoing surgery or biopsy - You are over 18 years old **You may NOT be eligible if...** - You are unable to give informed consent (for example, due to a cognitive or mental disability) - You are a vulnerable adult without capacity to consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.